Esophageal Diseases  >>  trebananib (AMG 386)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
trebananib (AMG 386) / Amgen
NCT00583674 / 2007-003573-50: Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma

Completed
2
171
US, Europe, RoW
AMG 386 placebo, AMG 386 10mg/kg, AMG 386 3mg/kg, Cisplatin, Capecitabine
Amgen
Gastrointestinal Cancer
03/10
06/12

Download Options